AYALA PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1792 USD | -14.67% |
|
-66.22% | -73.13% |
Presentation Operator MessageOperator (Operator)Welcome to the Advaxis Year-end Financials Res...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.21
Average target price
-
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -73.13% | 8.95M | |
| +27.45% | 48.16B | |
| -0.88% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +10.54% | 25.59B | |
| -22.83% | 18.96B | |
| +8.00% | 12.92B | |
| +29.29% | 12.03B | |
| -2.07% | 11.77B |
- Stock Market
- Equities
- ADXS Stock
- News Ayala Pharmaceuticals, Inc.
- Transcript : Advaxis, Inc., 2017 Earnings Call, Dec 21, 2017
